Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 13/20 | 0.55 |
| ▸ | CTSB | P07858 | 7/20 | 0.53 |
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701577 | 1.00 | CTSL (0.55) | CTSLCTSBCTSKCTSSALDH1A1 | |
| SCHEMBL6461875 | 0.91 | CTSL (0.63) | CTSLCTSBCTSKCTSS | |
| SCHEMBL5885617 | 0.90 | CTSK (0.53) | CTSLCTSBCTSKCTSSALDH1A1 | |
| SCHEMBL4961276 | 0.90 | CTSK (0.57) | CTSLCTSBCTSKCTSSALDH1A1 | |
| SCHEMBL13058656 | 0.90 | CTSK (0.57) | CTSLCTSBCTSKCTSSALDH1A1 | |
| SCHEMBL1667005 | 0.89 | CTSK (0.52) | CTSLCTSBCTSKCTSSALDH1A1 | |
| SCHEMBL16847591 | 0.88 | CTSL (0.62) | CTSLCTSBCTSKCTSS | |
| SCHEMBL3709555 | 0.88 | CTSK (0.55) | CTSLCTSBCTSKCTSSALDH1A1 | |
| SCHEMBL19017976 | 0.88 | CTSK (0.55) | CTSLCTSBCTSKCTSSALDH1A1 | |
| SCHEMBL1709147 | 0.88 | CTSL (0.67) | CTSLCTSBCTSKCTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8357683-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| WO-2007149512-A2 | PEPTIDE EPOXYKETONES FOR PR0TEAS0ME INHIBITION | PROTEOLIX, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSK 256/4885 |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSK 256/4885 |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSK 256/4885 |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSK 256/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSK 256/4885 |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSK 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.